

Table S2. Primer sequences for qPCR analysis

miRNA primers: For NanoString® validation in primary CPO patient cell cultures (RNU44 reference; five deregulated miRNAs).

Target gene primers: For predicted miRNA targets (RPL13 reference).

Transfection control primers: For monitoring transfection efficiency.

Note: Only primers yielding successful amplification are shown; failed assays were excluded.

miRNA	Forward	Reverse
hsa-miR-205-5p	ccttcattccaccggagt	gggccagtttttttttttcaga
hsa-miR-200c-3p	agtaatactgccgggtaatga	gggccagtttttttttttcca
hsa-miR-125a-5p	ccctgagaccctttaacct	gggccagtttttttttttcaca
hsa-miR-29b-3p	cagtagcaccatttgaaatcag	gggccagtttttttttttaaacac
hsa-miR-100-5p	cagaacccgtagatccga	gtccagtttttttttttcacaag
RNU44	cctggatgatgatagcaaatgc	gtccagtttttttttttagtcagt
Target gene	Forward	Reverse
AXIN2	CTTGACCCTGGGCCACTTTA	TTCATACATCGGGAGCACCG
CCNJ	CCAACGTGGCCTACAAGACT	TGCTTGCCCTCTCTGTTGT
CDK19	GATTTCAAGGCGAAGCTGGC	TCTCTCTACAAGCCGACATGG
JADE1	GTGTGCAAAGTCCAGGAACAG	TCAGGGCCAACAGAAGGACT
PAX9	CTTGAACCGTGAGGCTCCTT	CAGGAAACTCCTTCCGCTGT
HIPK3	TGAGTACCAGCTCCTCAGGG	CCGGAAGAGTCAGATGTCCG
NR5A2	TGCACAGGAGTTAGTGGCAA	GCGGCATTGACTTGTTCCTG
RECK	TGATGTATGTGAACAGATTTTCTCC	ACCCAGCCATCAGACTTCTT
TBK1	TGAGTCTCGAGGAGGCCG	AAGTGCTCTGCATCTTGGCT
VASH2	ACCCGAGAGTCCTTGCCTAT	CTGATGGGGAACCGCTCAAT
ZEB1	GCAGTCCAAGAACCACCCTT	CGCATTTTCTTTTGGGCGG
DVL3	ACATCTTCGGTGACCTCTGC	GGGTACTGGTACGGGAAAGC
MAP6	AGGAACCCCAAAGGTGGAA	AGTGCAGGGAAATTTACTCTTTG
PRSS35	GCTGAAGCGTGCTCACAAAA	GTCGGACACACTGCAAAACC
PRTG	CAGCCGCAGAGCAGAGAG	TAAAGCACCACACTCCTGGC
TNFSF4	TGGTGGTTGGGGTCACATTG	AGGATACCGATGTGATACCATGAG
RPL13	ATTCACAAGAAGGGAGACAG	GAAATTCTTCTCTTCCTCAGTG
Reference transfection gene	Forward	Reverse
HMGA2	GAAAAACGCCCAAGAGGCAG	GATCCAAGTCTGCTGAGGT
PTK9	GCAGTATAAGAGAGCGGATGCT	ACTCATCCCCATTGTCTATCTCG